Pharmafile Logo
Pharmafocus logo
Advanced Search

Avecia Biotech sold to Nitto Denko

February 8, 2011
Manufacturing and Production Avecia, Avecia Biologics, Avecia Biotechnology, Nitto Denko

Avecia Biotechnology, which focuses mainly on the development and manufacturing of oligonuceotide medicines, has been acquired by Japanese firm Nitto …

News
AstraZeneca's Iressa (gefitinib)

AZ and Pfizer support personalised medicine database

February 8, 2011
Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine

AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …

News

Merck KGaA appoints Frederic Wohlwend

February 7, 2011
Sales and Marketing Frederic Wohlwend, Merck KGaA, appointment, sales and marketing

Frederic Wohlwend has been promoted to chief information officer at Merck KGaA with effect from 1 April. He succeeds Kai …

Appointment
Pfizer research Sandwich, Kent

Pressure mounts on Pfizer and government over UK R&D closure

February 7, 2011
Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee

The political fallout over Pfizer’s decision to close its Kent R&D base continues apace, with the House of Commons to …

News

Late-stage blow to AstraZeneca’s prostate cancer drug

February 7, 2011
Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan

A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …

News
Roche's Avastin (bevacizumab)

Survey shows doctors support FDA Avastin decision

February 7, 2011
Sales and Marketing FDA, Roche, Sermo, avastin, bevacizumab

A survey of US doctors suggests that a majority support the FDA’s decision to take away Avastin’s licence for use …

News

GSK profits slump amid ongoing Avandia woes

February 7, 2011
Sales and Marketing 2010 pharma results, Avandia, GSK, GlaxoSmithKline

GlaxoSmithKline’s ongoing woes with diabetes drug Avandia hit profits in 2010. Profits after tax plummeted 56% to £3 billion for …

News

Merck dipped into the red as 2010 ended

February 4, 2011
Sales and Marketing 2010 pharma results, Merck & Co

Merck & Co made a $531 million loss in the final quarter of 2010 – down from a profit of …

News
Merck Serono cancer disease awareness campaign

Digital Pharma: Merck Serono launches campaign for cancer carers

February 4, 2011
Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer

Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …

News

Bayer’s regorafenib gains orphan status for GIST

February 4, 2011
Research and Development, Sales and Marketing Bayer, FDA, GIST, gastrointestinal stromal tumours, orphan drug, regorafenib

Bayer’s investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumours (GIST) …

News

Sparkling celebrations at PM Awards’ silver jubilee

February 4, 2011
Medical Communications Langland, PM Society Advertising Awards, advertising, awards, pm society

The PM Society marked the 25th anniversary of its annual advertising awards with a ceremony that glittered almost as much …

Feature

Bayer and Zydus Cadila sign India deal

February 4, 2011
Sales and Marketing Bayer, India, Indian pharmaceutical industry, Zydus Cadila

Bayer HealthCare and the Indian company Zydus Cadila have signed a deal to form a new joint venture. A new …

News
Pfizer research Sandwich, Kent

ABPI backs UK science after Pfizer’s R&D exit

February 4, 2011
Research and Development Kent, Pfizer, Sandwich

The ABPI has defended the UK’s research environment against mounting criticism following Pfizer’s decision to close its Kent research base. …

News
lec_kim_hughes

LEC appoints joint creative directors

February 4, 2011
Medical Communications Harry Armfield, Kim Hughes, LEC, Lane Earl Cox, appointment, medical communications

Lane Earl Cox has promoted Harry Armfield and Kim Hughes to the position of joint creative directors. Harry and Kim …

Appointment

Working Life: Merck Sharp & Dohme medical director Paul Robinson

February 4, 2011
Business Services, Research and Development MSD, Paul Robinson, Working Life, careers, merck sharp and dohme, recruitment

Paul Robinson, medical director at Merck Sharp & Dohme, looks at how his field is changing, the most enjoyable things …

News

Pressure mounts on Servier over Mediator controversy

February 3, 2011
Sales and Marketing France, G5, Mediator, Servier, benfluorex

Dr Jacques Servier has stepped down from his role as head of a French pharma industry association as controversy grows …

News

Five capabilities of centered leadership

February 3, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Caroline Webb, Joanna Barsh, Josephine Mogelof, McKinsey & Company, leadership

The business environment has become more demanding: the global financial crisis and subsequent economic downturn have ratcheted up the pressure …

Feature

Pfizer appoints Dr Yvonne Greenstreet to specialty care business

February 3, 2011
Research and Development Dr Yvonne Greenstreet, Pfizer, appointment, specialty care

Dr Yvonne Greenstreet has joined Pfizer to head up medicines development for its Specialty Care business unit. She moves to …

Appointment
Roche Severin Schwann

Roche weathers tough year and looks to pipeline for 2011

February 3, 2011
Research and Development, Sales and Marketing 2010 pharma results, BRAF protein, GDC-0449, RG3616, RG7204, Roche, avastin, pertuzumab

Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …

News

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026